Regeneron Stock Rises on Strong Second-Quarter Results
Shares of Regeneron Pharmaceuticals (REGN) rose in premarket trading after the company reported better-than-expected second-quarter 2026 results. The strong performance was driven by increased sales from a high-dose version of its eye therapy, Eylea. The drugmaker's financials beat Wall Street estimates, signaling robust demand for Regeneron’s products and positive momentum in the ophthalmology sector. This result has boosted investor confidence ahead of regular trading hours. Analysts suggest that this performance could reinforce Regeneron's position as a key player in innovative therapies, potentially influencing broader market sentiment toward pharmaceutical stocks.
Tickers: $REGN
Topics: Eye Therapy Pharmaceuticals Q2 Earnings